J Gynecol Oncol.
2015 Jan;26(1):46-53. 10.3802/jgo.2015.26.1.46.
Distinguishing benign from malignant pelvic mass utilizing an algorithm with HE4, menopausal status, and ultrasound findings
- Affiliations
-
- 1Department of Obstetrics and Gynecology, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand. sarikapan.wil@mahidol.ac.th
- 2Department of Obstetrics and Gynecology, University of Hong Kong, Hong Kong.
- 3Department of Obstetrics and Gynecology, National Taiwan University Hospital, Taipei, Taiwan.
- 4Department of Obstetrics and Gynecology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
- 5Department of Obstetrics and Gynecology, The Jikei University, Tokyo, Japan.
- 6Department of Laboratory Medicine, Changi General Hospital, Singapore.
- 7Department of Pathology, Hospital Sultanah Aminah, Johor Bahru, Johor, Malaysia.
- 8Abbott Diagnostics, Abbott Park, IL, USA.
- 9Department of Obstetrics and Gynecology, MCU-FDT Medical Foundation, Caloocan, Philippines.
- KMID: 2158802
- DOI: http://doi.org/10.3802/jgo.2015.26.1.46
Abstract
OBJECTIVE
The purpose of this study was to develop a risk prediction score for distinguishing benign ovarian mass from malignant tumors using CA-125, human epididymis protein 4 (HE4), ultrasound findings, and menopausal status. The risk prediction score was compared to the risk of malignancy index and risk of ovarian malignancy algorithm (ROMA).
METHODS
This was a prospective, multicenter (n=6) study with patients from six Asian countries. Patients had a pelvic mass upon imaging and were scheduled to undergo surgery. Serum CA-125 and HE4 were measured on preoperative samples, and ultrasound findings were recorded. Regression analysis was performed and a risk prediction model was developed based on the significant factors. A bootstrap technique was applied to assess the validity of the HE4 model.
RESULTS
A total of 414 women with a pelvic mass were enrolled in the study, of which 328 had documented ultrasound findings. The risk prediction model that contained HE4, menopausal status, and ultrasound findings exhibited the best performance compared to models with CA-125 alone, or a combination of CA-125 and HE4. This model classified 77.2% of women with ovarian cancer as medium or high risk, and 86% of women with benign disease as very-low, low, or medium-low risk. This model exhibited better sensitivity than ROMA, but ROMA exhibited better specificity. Both models performed better than CA-125 alone.
CONCLUSION
Combining ultrasound with HE4 can improve the sensitivity for detecting ovarian cancer compared to other algorithms.
Keyword
MeSH Terms
-
Adult
*Algorithms
Biomarkers, Tumor/*blood
CA-125 Antigen/blood
Decision Support Techniques
Diagnosis, Differential
Female
Humans
Menopause
Middle Aged
Ovarian Neoplasms/*diagnosis/ultrasonography
Predictive Value of Tests
Prospective Studies
Proteins/*analysis
ROC Curve
Risk Assessment/methods
Sensitivity and Specificity
Biomarkers, Tumor
CA-125 Antigen
Proteins
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Human Epididymis Protein 4 as a Diagnostic Marker of Ovarian Cancer and Its Reference Interval in Korean Population
- Comparison of HE4, CA125, and Risk of Ovarian Malignancy Algorithm in the Prediction of Ovarian Cancer in Korean Women
- Discrimination between Benign and Malignant Pelvic Masses Using the Risk of Malignancy Index 1
- Performance Evaluation of the ARCHITECT HE4 Assay
- Four risk of malignancy indices in evaluation of pelvic masses
